title: [The levels of plasminogen and inhibitor of plasminogen activators of type 1 in antiphospholipid syndrome].
abstract: OBJECTIVE
  To estimate the levels of of plasminogen (Pg) and inhibitor of plasminogen activators of type 1 (IPA-1) in patients with antiphospholipid syndrome (APS) and to reveal correlations between their content and clinical-laboratory characteristics of APS.
  
  
  METHODS
  A Pg level was measured in 78 APS patients: 35 of them had systemic lupus erythematosus (SLE), 43 had primary APS and 19 with idiopathic thrombosis (IT). IPA-1 was detected in 63 APS patients: in 26, 37 and 18 patients, respectively. The control group consisted of 10 subjects free of autoimmune disease and thrombosis. The patients were matched by age. Pg and IPA-1 levels were estimated kinetically. The Pg level was stratified. normal (1.5-2.0 mcM high (above 2.0 mcM), low (under 1.5 mcM). Thromboses in the past occurred in 67 patients: arterial (n=32), venous (n=53), of combined localization (n=14).
  
  
  RESULTS
  Of 78 APS patients, Pg level was normal in 34 (44%), high--in 20 (25%), low--in 24 (31%). Of 43 primary APS patients, low Pg was in 8 (19%), of 35 patients with SLE+APS--in 16 (46%) patients. A Pg concentration (1.59 [1.4; 1.98] mcM) was significantly less in APS patients with thrombosis than in patients with IT (2.4 [1.74; 2.99] mcM). Pg tended to lower levels than in the controls (1.95 [1.63; 2.26] mcM). IPA-I varied in primary APS from 0.45 to >1 nM, in SLE+APS--from 0.44 to >1 nM, in IT--from 0.65 to 0.81 nM. The levels of active IPA-1 in all the patients with APS and IT were higher than in healthy donors and varied from 0.44 to >1 nM Most of APS patients had high level of IPA-1--52 (83%) (IPA-1 from 0.1 to 1), of them 22 (85%) patients with SLE+APS and 30 (73%)--with primary APS. 11 (17%) APS patients had high IPA-1 (>1), of them 4 (15%) with SLE+APS and 7 (27%) with primary APS. All IT patients had moderately high IPA-1 level.
  
  
  CONCLUSIONS
  A low level of Pg in APS patients was seen significantly more frequently than in IT patients and controls and was associated with thrombosis, primarily arterial. Moderate high IPA-1 occurred in 83% of 63 APS patients, high--in 17%. IT patients had moderately high IPA-1. High IPA-1 was associated in APS with thrombosis, primarily arterial.
mesh_terms: D000328:Adult; D016736:Antiphospholipid Syndrome / Q000453:epidemiology / Q000503:physiopathology*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000453:epidemiology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010958:Plasminogen / Q000378:metabolism*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism*; D013927:Thrombosis / Q000453:epidemiology / Q000503:physiopathology*; D055815:Young Adult
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D010958:Plasminogen